181 related articles for article (PubMed ID: 21647156)
1. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Leukemia; 2011 Oct; 25(10):1587-97. PubMed ID: 21647156
[TBL] [Abstract][Full Text] [Related]
2. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Tanaka H; Nakashima S; Usuda M
Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
[TBL] [Abstract][Full Text] [Related]
3. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
4. Large granular lymphocytosis during dasatinib therapy.
Qiu ZY; Xu W; Li JY
Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
[TBL] [Abstract][Full Text] [Related]
5. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
[TBL] [Abstract][Full Text] [Related]
6. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
[TBL] [Abstract][Full Text] [Related]
7. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph
Ishiyama K; Kitawaki T; Sugimoto N; Sozu T; Anzai N; Okada M; Nohgawa M; Hatanaka K; Arima N; Ishikawa T; Tabata S; Onaka T; Oka S; Nakabo Y; Amakawa R; Matsui M; Moriguchi T; Takaori-Kondo A; Kadowaki N
Leukemia; 2017 Jan; 31(1):203-212. PubMed ID: 27349810
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
Ishiyama KI; Kitawaki T; Otsuka Y; Takaori-Kondo A; Kadowaki N
Cancer Sci; 2021 Feb; 112(2):523-536. PubMed ID: 33064914
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
[TBL] [Abstract][Full Text] [Related]
11. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.
Shimura Y; Horiike S; Tsutsumi Y; Hatsuse M; Okano A; Fuchida S; Kobayashi T; Matsumoto Y; Kuroda J; Kawata-Iida E; Uchiyama H; Uoshima N; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
Int J Hematol; 2015 Oct; 102(4):426-33. PubMed ID: 26267232
[TBL] [Abstract][Full Text] [Related]
12. NKG2C
Grutza R; Moskorz W; Senff T; Bäcker E; Lindemann M; Zimmermann A; Uhrberg M; Lang PA; Timm J; Cosmovici C
J Immunol; 2020 Jun; 204(11):2910-2917. PubMed ID: 32284334
[TBL] [Abstract][Full Text] [Related]
13. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus.
Havenith SH; Remmerswaal EB; Bemelman FJ; Yong SL; van Donselaar-van der Pant KA; van Lier RA; Ten Berge IJ
Clin Exp Immunol; 2012 Sep; 169(3):292-301. PubMed ID: 22861369
[TBL] [Abstract][Full Text] [Related]
14. Independent skewing of the T cell and NK cell compartments associated with cytomegalovirus infection suggests division of labor between innate and adaptive immunity.
Bengnér M; Béziat V; Ernerudh J; Nilsson BO; Löfgren S; Wikby A; Malmberg KJ; Strindhall J
Age (Dordr); 2014 Apr; 36(2):571-82. PubMed ID: 24065293
[TBL] [Abstract][Full Text] [Related]
15. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Hayashi Y; Nakamae H; Katayama T; Nakane T; Koh H; Nakamae M; Hirose A; Hagihara K; Terada Y; Nakao Y; Hino M
Leuk Lymphoma; 2012 Jun; 53(6):1084-9. PubMed ID: 22211798
[TBL] [Abstract][Full Text] [Related]
16. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
[TBL] [Abstract][Full Text] [Related]
17. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
[TBL] [Abstract][Full Text] [Related]
18. T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57.
Melenhorst JJ; Eniafe R; Follmann D; Molldrem J; Kirby M; El Ouriaghli F; Barrett AJ
Hematol J; 2003; 4(1):18-25. PubMed ID: 12692516
[TBL] [Abstract][Full Text] [Related]
19. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
García-Muñoz R; Galar A; Moreno C; Rodríguez-Otero P; Panizo-Morgado E; Ponz-Sarvisê M; Fernandez-Alonso M; Rubio M; Merino J; Cuesta B; Panizol C; Prosper F
Leuk Lymphoma; 2007 Dec; 48(12):2461-4. PubMed ID: 18067026
[No Abstract] [Full Text] [Related]
20. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Hassold N; Seystahl K; Kempf K; Urlaub D; Zekl M; Einsele H; Watzl C; Wischhusen J; Seggewiss-Bernhardt R
Int J Cancer; 2012 Sep; 131(6):E916-27. PubMed ID: 22419518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
